BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1469-1476

  Huang, Yen T A ^a,b   Lai, Pei Chun ^a,b   Wu, Chia Chen ^b   Hsu, Shih Hsin ^a   Cheng, Chuan Chu ^b   Lan, Y I Fan ^a   Chiu, Ted H ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

BDNF; Bladder cancer; Transitional cell carcinoma; TrkB; Xenograft

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CHIMERIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANOIKIS; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; RECEPTOR, TRKB; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951544990     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000633     Document Type: Article

References (43)

1. Parkin D: The global burden of urinary bladder cancer. Scand J Urol Nephrol 218: 12-20, 2008.
2. Bellmunt J, Albiol S, Suarez C and Albanell J: Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Criti Rev Oncol Hematol 69: 211-222, 2009.
3. Calabro F and Sternberg CN: High-risk metastatic urothelial cancer: chances for cure? Curr Opin Urol 12: 441-448, 2002.
4. Huang EJ and Reichardt LF: Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677-736, 2001. (Pubitemid 32695243)
5. Shibayama E and Koizumi H: Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues. Am J Pathol 148: 1807-1818, 1996.
6. Lommatzsch M, Braun A, Mannsfeldt A, Botchkarev VA, Botchkareva NV, Paus R, Fischer A, Lewin GR and Renz H: Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived neurotrophic functions. Am J Pathol 155: 1183-1193, 1999. (Pubitemid 29488926)
7. Aoyama M, Asaib K, Shishikurac T, Kawamoto T, Miyachi T, Yokoi T, Togari H, Wada Y, Kato T and Nakagawara A: Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants. Cancer Lett 164: 51-60, 2001. (Pubitemid 32144989)
8. Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA and Ruggeri BA: Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer 81: 417-427, 1999. (Pubitemid 29165201)
9. Montano X and Djamgoz MB: Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett 571: 1-8, 2004. (Pubitemid 38992914)
10. Ricci A, Greco S, Mariotta S, Felici L, Bronzetti E, Cavazzana A, Cardillo G, Amenta F, Bisetti A and Barbolini G: Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol 25: 439-446, 2001. (Pubitemid 33037676)
11. Yang ZF, Ho DW, Lam CT, Luk JM, Lum CT, Yu WC, Poon RT and Fan ST: Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res 65: 219-225, 2005.
12. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, van Garderen E and Peeper DS: Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034-1039, 2004.
13. Yu X, Liu L, Cai B, He Y and Wan X: Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci 99: 543-552, 2008. (Pubitemid 351228572)
14. Nakagawara A: Trk receptor tyrosine kinases: a bridge between cancer and neural development (review). Cancer Lett 169: 107-114, 2001.
15. Pierotti MA and Greco A: Oncogenic rearrangements of the NTRK1/NGF receptor (review). Cancer Lett 232: 90-98, 2006.
16. Dollé L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V and Hondermarck H: Nerve growth factor receptors and signaling in breast cancer (review). Curr Cancer Drug Targets 4: 463-470, 2004. (Pubitemid 39304490)
17. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V and Evans AE: Trk receptor expression and inhibition in neuroblastomas (review). Clin Cancer Res 15: 3244-3250, 2009.
18. Tzeng CC, Liu HS, Li C, Jin YT, Chen RM, Yang WH and Lin JS: Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Anticancer Res 16: 1797 - 1804, 1996.
19. Yeh MY, Yu DS, Chen SC, Lin MS, Chang SY, Ma CP and Han SH: Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). J Surg Oncol 37: 177-184, 1988. (Pubitemid 18095867)
20. Chao JI, Su WC and Liu HF: Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol Cancer Ther 6: 3039-3048, 2007.
21. Liu YN, Liu Y, Lee HJ, Hsu YH and Chen JH: Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol 28: 7096-7108, 2008.
22. Chao JI, Kuo PC and Hsu TS: Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 279: 20267-20276, 2004. (Pubitemid 38623472)
23. Slack SE, Grist J, Mac Q, McMahon SB and Pezet S: TrkB expression and phospho-ERK activation by brain-derived neurotrophic factor in rat spinothalamic tract neurons. J Comp Neurol 489: 59-68, 2005. (Pubitemid 40934673)
24. Sugimoto T, Kuroda H, Horii Y, Moritake H, Tanaka T and Hattori S: Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells. Jpn J Cancer Res 92: 152-160, 2001. (Pubitemid 32237093)
25. Karlou M, Saetta AA, Korkolopoulou P, Levidou G, Papanastasiou P, Boltetsou E, Isaiadis D, Pavlopoulos P, Thymara I, Thomas-Tsagli E and Patsouris E: Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology 41: 327-334, 2009.
26. Anger DL, Zhang B, Boutross-Tadross O and Foster WG: Tyrosine receptor kinase B (TrkB) protein expression in the human endometrium. Endocrine 31: 167-173, 2007. (Pubitemid 350195152)
27. Iwabe S, Moreno-Mendoza NA, Trigo-Tavera F, Crowder C and Garcia-Sanchez GA: Retrograde axonal transport obstruction of brain-derived neurotrophic factor (BDNF) and its TrkB receptor in the retina and optic nerve of American Cocker Spaniel dogs with spontaneous glaucoma. Vet Ophthalmol 10: 12-19, 2007. (Pubitemid 350007140)
28. Bretland AJ, Lawry J and Sharrard RM: A study of death by anoikis in cultured epithelial cells. Cell Prolif 34: 199-210, 2001. (Pubitemid 32738643)
29. Simpson CD, Anyiwe K and Schimmer AD. Anoikis resistance and tumor metastasis (review). Cancer Lett 272: 177-185, 2008.
30. Choi EM, Kwak SJ, Kim YM, Ha KS, Kim JI, Lee SW and Han JA: COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med 37: 199-203, 2005.
31. Uehara N, Matsuoka Y and Tsubura A: Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 6: 186-193, 2008. (Pubitemid 351342406)
32. Bindels EM, Vermey M, De Both NJ and van der Kwast TH: Influence of the microenvironment on invasiveness of human bladder carcinoma cell lines. Virchows Arch 439: 552-559, 2001. (Pubitemid 32930182)
33. Su SJ, Yeh TM, Lei HY and Chow NH: The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 6: 230-236, 2000.
34. Albert SE, McKerlie C, Pester A, Edgell BJ, Carlyle J, Petric M and Chamberlain JW: Time-dependent induction of protective anti-influenza immune responses in human peripheral blood lymphocyte/SCID mice. J Immunol 159: 1393-1403, 1997. (Pubitemid 127484118)
35. Pearse RN, Swendeman SL, Li Y, Rafii D and Hempstead BL: A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood 105: 4429-4436, 2005. (Pubitemid 40720791)
36. Yang ZF, Ho DW, Lau CK, Tam KH, Lam CT, Poon RT and Fan ST: Platelet activation during tumor development, the potential role of BDNF-TrkB autocrine loop. Biochem Biophys Res Commun 346: 981-985, 2006. (Pubitemid 43913704)
37. Binder DK, Routbort MJ, Ryan TE, Yancopoulos GD and McNamara JO: Selective inhibition of kindling development by intraventricular administration of TrkB receptor body. J Neurosci 19: 1424-1436, 1999.
38. Miletic G and Miletic V: Loose ligation of the sciatic nerve is associated with TrkB receptor-dependent decreases in KCC2 protein levels in the ipsilateral spinal dorsal horn. Pain 137: 532-539, 2008. (Pubitemid 351970171)
39. Yajima Y, Narita M, Usui A, Kaneko C, Miyatake M, Narita M, Yamaguchi T, Tamaki H, Wachi H, Seyama Y and Suzuki T: Direct evidence for the involvement of brain-derived neurotrophic factor in the development of a neuropathic pain-like state in mice. J Neurochem 93: 584-594, 2005. (Pubitemid 40617618)
40. Geiger TR and Peeper DS: Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis (review). Cancer Res 67: 6221-6229, 2007.
41. Thiele CJ, Li Z and McKee AE: On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology (review). Clin Cancer Res 15: 5962-5967, 2009.
42. Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C and Bologna M: Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol 30: 193-200, 2007.
43. Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J and Berlin J: A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 26: 241-247, 2008.